1Fe-LSD

1Fe-LSD
Clinical data
Other names1-(Ferrocenecarbonyl)-LSD; (8β)-1-Ferrocenecarbonyl-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide; SYN-L-234
Routes of
administration
Oral[1][2]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
CAS Number
Chemical and physical data
FormulaC31H33FeN3O2
Molar mass535.469 g·mol−1
3D model (JSmol)
  • CCN(C([C@H]1CN(C)[C@]2([H])Cc3c4c(C2=C1)cccc4n(C(c5ccc[cH-]5)=O)c3)=O)CC.c6[cH-]ccc6.[Fe+2]
  • InChI=InChI=1S/C26H28N3O2.C5H5.Fe/c1-4-28(5-2)25(30)19-13-21-20-11-8-12-22-24(20)18(14-23(21)27(3)15-19)16-29(22)26(31)17-9-6-7-10-17;1-2-4-5-3-1;/h6-13,16,19,23H,4-5,14-15H2,1-3H3;1-5H;/q2*-1;+2/t19-,23-;;/m1../s1
  • Key:IIOLYFVNUDARGZ-CHOFETAFSA-N

1Fe-LSD, also known as 1-(ferrocenecarbonyl)-LSD or as SYN-L-234, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3] It is thought to be a prodrug of LSD.[1][2][3] The drug was patented by Lizard Labs in 2024.[3] Subsequently, it was encountered online as a novel designer drug being sold in Germany in November 2025.[1][2] 1Fe-LSD as the hemi-L-tartrate salt has been sold in the form of blotter containing 200 μg per tab and micropills containing 300 μg per pill.[1][2] 1Fe-LSD contains ferrocene, an iron compound, which is an orange organometallic compound and is assumed to result in the distinctive orange color of 1Fe-LSD blotter and pills.[1][2]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "1Fe-LSD". AIPSIN (in Russian). Retrieved 1 January 2026.
  2. ^ a b c d e f Yurchenko R, Yurchenko L, Galetskaya I, Navitski M (November 2025). Psychoactive products market observation. Trend analysis. Recent trends in the identification of psychoactive substances. doi:10.13140/RG.2.2.17433.68969. Retrieved 1 January 2026.
  3. ^ a b c WO 2024/028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV 
[edit]